ArticleTrials2026

Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview study.

Elizabeth Merikle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.